Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Lockheed Martin opens new hypersonic weapons facility - 2Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- 3Exploring the Gig Economy: Illustrations from Consultants
- 4Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- 52023's Best 10 Cell phone Advancements You Can't Miss
- Creative Tech Contraptions That Will Work on Your Life
- The Electric Bicycle Americans Can Confide in 2024
- China’s new condom tax will prove no effective barrier to country’s declining fertility rate
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- 6 US States for Fly Fishing
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
